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Critically septic patients carry high mortality; however, it may be ame-
liorated to some extent by the appropriate prescription of antimicro-
bials and appropriate dosing strategy. Drug metabolism in critically 
septic patients differ from other less critical patients, and antimicrobial 
treatment need to be adjusted to prevent under dosing. The augmen-
ted clearance, acute kidney injury, microvascular ischemia, all affect 
antimicrobials’ levels. Methods of antimicrobial administration were 
explored, continuous infusion versus intermittent bolus, with the aim 
of maximizing drug exposure, hitherto, apart from PK/PD advantage, it 
was not translated clearly into patients’ clinical outcome. Biofilms have 
a unique management as they need elevated antimicrobial dosages to 
assure adequate drug exposure, and agents that work directly on bio-
films to assure its disruption. Application of PK/PD knowledge in the 
management of critically septic patients maximize the clinical outcome 
and assures proper drug exposure, avoiding under dosing and drug 
toxicity, and decreasing the chance of antimicrobials mutant’s selec-
tion, and therapy failures.
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Introduction
The prevalence of infection in ICU is high,bearing in mind both ad-
mitted patients with sepsis and those who acquire new ICU-related 
nosocomial sepsis, but the latter is noted to be associated with hig-
her mortality despite similar severity scores [1, 2]. The incidence and 
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prevalence of sepsis increase with age, the older 
age groups carry higher incidence and it is increa-
sed >100-fold (0.2/1,000 in children to 26.2/1,000 
in patients >85 years old), also, hospital mortality 
increases with age, from 10% in children to 38.4% 
in those >85 years old [3], with an average mor-
tality of 37.5% in critically septic patients, and if 
combined with renal replacement therapy morta-
lity reaches up to 50% [4, 5]. Furthermore, sepsis 
prevalence increased in the last few decades, a 
USA study identified about 8.5 million patients and 
found significant increase in sepsis prevalence from 
1993 to 2003, and the percentage of severe sep-
sis (among all sepsis cases) increased continuously 
from 25.6% in 1993 to 43.8% in 2003 (p < .001), 
age adjusted mortality rates increased whereas-
hospital case fatality rate fell from 45.8 - 37.8% 
(p < .001) [6, 7]. 
The rapid management of sepsis is crucial in the 
first 6 hours, and mortality increases in hourly de-
lays even within the first 6 hours time frame, es-
pecially in patients with higher severity scores [8], 
hourly delay in antibiotic administration will cause 
mortality: 0.3% (P =0.04) for sepsis; 0.4% (P =0.02) 
for severe sepsis; and 1.8% (P =0.001) for septic 
shock [9]. Septic patients are mostly being treated 
empirically before the availability of microbiologi-
cal diagnosis. Appropriate antimicrobial use and 
attention to patients’details leads to a better early 
goal directed antimicrobial therapy. The empiric 
and appropriate use of antimicrobials contributes 
to decrease mortality in critically septic patients, 
the initial evaluation of patients, the knowledge of 
sepsis source is crucial to the design of the antimi-
crobial therapeutic intervention, and availability of 
surveillance data is important whether sepsis origin 
is SSTI, lungs, urinary or other sources. Further-
more, primary bacteremia disposes a remarkable 
decrease in survival in case of inappropriate anti-
microbial therapy when compared with sepsis of 
urinary origin [10, 11, 12, 13]. 
PK/PD effects on dosing strategies
Many Factors may hamper antimicrobials’ exposure 
in critically septic patients, often they have capi-
llary leak that increases the volume of distribution 
(Vd), augments renal clearance and alters protein 
bindings. All these factors may compromise antimi-
crobial blood levels, and decrease the antimicrobials 
exposure. However, end stage septic patients with 
organs failure or multi-organ dysfunction syndro-
me (MODS) demonstrate decreased clearance, and 
alerting high drug levels may be attained [14]. On 
the other hand, attention must be paid for the de-
velopment of acute kidney injury (AKI), which is not 
uncommon in it affects septic patients of various 
severity scores, it affects about 10% of admitted 
septic patients, and it has an impact on antimicro-
bials blood levels, and exposure. [15]. 
Optimization of antimicrobial therapy in critica-
lly septic patients, keeping in mind safety, efficacy, 
avoiding suboptimal drug levels, and elevated toxic 
levels, by observing kidney function among other 
factors, then customizing doses. Here, therapeutic 
drug monitoring (TDM) are needed, especially in 
antimicrobial agents with narrow therapeutic in-
dex (TI), (Figure 1) [16, 17]. β-lactam antimicrobial 
agents need to be adjusted mostly based on clea-
rance, and calculated body weight, as their TI is 
wide. Nevertheless, even β-lactams antimicrobials 
are subjected to TDM in many parts of the world 
to assure drug exposure, though no clear clinical 
benefits of β-lactam TDM was evident outside the 
critically septic patients [18]
Bacterial killing is highly dependent on the sus-
ceptibility break points, minimum inhibitory concen-
tration (MIC). However, incorporating PK/PD princi-
ples to the MIC is crucial in the understanding of 
the differences of bacterial killings for different anti-
microbials, doses, and their methods of administra-
tion. This was evident in the preclinical antimicrobial 
studies for different set points like explaining better 
efficacy, and in clinical studies explaining better effi-
cacy or lack of response [19]. 
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Types of PK/PD bacterial killingand 
efficacy
Currently, the known three methods of bacterial ki-
lling are: Time dependent, concentration dependent 
and mixed pattern killing. The free drug component 
may be the major determinant for efficacy, howe-
ver, there is “no standardization for pharmacodyna-
mic models that account for the impact of protein 
binding of antimicrobial agents in vitro” and no 
consensus about a protein binding model, whether 
animals or human protein which are used to assess 
antimicrobial efficacy, and whether in vitro studies 
apply to in vivo studies [20]. 
The time dependent bacterial killing (efficacy in-
dex T>MIC, and fT>MIC) is highly reliable on the 
duration of attaining sufficient antimicrobial levels 
above MIC (preferably 4 x MIC) for an established 
duration of the dosing interval, usually >40%, with 
some variations among β-lactam antibiotics. The 
concentration dependent bacterial killing (efficacy 
index Cmax/MIC or fCmax/MIC) is related to how 
highthe administered drug dose level is attained 
in an individual, without stressing on the duration 
of drug level above MIC and trough levels, the 
agents that follow this pattern have a post anti-
biotic effect (PAE) to span the rest of the dosing 
interval. The aim is to keep Cmax/MIC target e.g. 
for aminoglycosides at about 10-12. The mixed 
pattern bacterial killing (efficacy index AUC/MIC, 
or fAUC/MIC) is a mix of both above two types 
of bacterial killing, where both the drug concen-
tration and its duration above MIC for a sufficient 
duration of time matters, and the target is custo-
mized based on the microorganism and infection 
being treated (Figure 2) [21]. 
In the animal model, it was evident that the 
methods of bacterial killing is different for various 
antimicrobials classes, for some antimicrobials that 
follow time-dependency (T>MIC), if studied under 
different circumstances they fail to show a trustable 
bacterial killing; taking Ceftobiprole as an example 
for killing S. aureus, where both Cmax/MIC and 
AUC/MIC did not correlate well as T>MIC, while 
gatifloxacin, a quinolone that is mostly has a mixed 
PK/PD bacterial killing pattern (AUC/MIC) fails to 
do well when tested on T>MIC scale (Figure 3). [19, 
22]. The same phenomena are also valid for other 
Figure 1:  Schematic explanation of the relationship 
between a hypothetical two antibiotics, 
concentration versus effects, whether 
response or toxicity. Note that for any 
drug concentration point examined for 
the antibiotic in figure (A), there is wide 
difference between response and toxici-
ty denoting safer than the hypothetical 
second antibiotic (B), where a similar 
drug concentration point examined de-
picts closer distance between response 
and toxicity i.e. relatively less safe anti-
biotic and TDM is a must [16, 17]. 
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Figure 2:  The PK/PD patterns of bacterial killing. (A) ƒT>MIC shows the time spent above the antimi-
crobial MIC for the treated bacteria, (B) ƒCmax/MIC which is the maximum concentration 
an antimicrobial reach over MIC, and (C) ƒAUC/MIC, a mixed pattern of bacterial killing, it 
depends on how much antimicrobial was available and its duration above the MIC [21]. 
Figure 3:  Correlation of ceftobiprole (A) (β–Lactam )PK/PD indices with efficacy against a strain of S. 
aureus. Note that the coefficient of determination, shows stronger association for ƒT>MIC, 
r2 = .85. Less for the AUC/MIC due to time component and very poor for the Cmax/MIC. 
Mouse thigh model was used, each circle represent the average of two from both thighs. (B) 
On the other hand, Salmonella two strains were tested with gatifloxacin, it showed the best 
activity with ƒAUC/MIC with, r2 = .94 [19, 22]. 
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classes of antimicrobials that have concentration de-
pendent kinetics with fCmax/MIC as the index of 
activity. A clear example on this killing pattern are 
Aminoglycosides (Figure 2B), whose attaining high 
peak levels correlates better with activity, in addition 
they have post-antibiotic effect (PAE) that bridge the 
blood absent drug level. Other agents have a similar 
efficacy index like Fluoroquinolones, Daptomycin, 
GLycopeptides, Amphotericin B, and Echinocandins 
[23]. The third type of PK/PD bacterial killing is the 
mixed pattern, and that is dependent on both attai-
ning a sufficient concentration for a sufficient time 
above the antimicrobial MIC, examples are Fluoro-
quinolones, Daptomycin, GLycopeptides, Ketolides, 
Macrolides, Clindamycin, Streptogramins, Oxazoli-
donoes, Tetracyclines, Glycycyclines, Aminoglycosi-
des, Triazoles, and Echinocandins (Figure 2C) [24]. 
Clinical correlate of PK/PD and its 
applicationin septic patients
Physicochemical properties of antimicrobials and 
dosage requirements in the presence of severe 
sepsis in critically sick patients do matter, the con-
centration of the “hydrophilic” antimicrobials like 
aminoglycosides, β-lactams, GLycopeptides and Li-
popeptides are highly extracellularly distributed, the 
interplay of many factorsmay cause antimicrobials 
to be increased or decreasedinearly sepsis-induced 
augmented clearance or decreased renal clearance 
due to AKI respectively, and dosages need to be ad-
justed accordingly. However, “lipophilic” antimicro-
bials like tetracyclines, fluoroquinolones, glycylcycli-
nes, ketolides, macrolides, metronidazole, strepto-
gramins, are all highly intracellularly distributed and 
predominantly hepatically cleared, and their dose 
modification is marginal to non [25, 26, 27]. 
In β-lactams-treated animal model, S. pneumo-
niae infected animals demonstratedimproved survi-
val as T>MIC attain higher than 40%of dosing in-
terval target. Human clinical trials on antimicrobials 
in the treatment of critically septic patients applying 
PK/PD were reported. PK/PD parameters proved in 
human to work well for T>MIC in otitis media mo-
del, where the correlation of the target attainment 
and cure when using penicillin to treat S. pneu-
moniae and H. influenzae was evident, and cure 
of more than 80% of patients occurred in whom≥ 
40% target was attained [28]. The same phenome-
na were evident with the 24 hours AUC/MIC when 
target attained over 125 mg.hr/Lhas been met on 
treating gram-positive and gram-negative bacteria. 
Daptomycin was also evaluated in critically septic 
patients with shock and high SOFA scoresdue to 
MRSA bacteremia. Significantly lower daptomycin 
exposures were observed despite comparable doses 
in a subset of patients with augmented clearance, 
and the probability of target attainment was not 
achieved in all patients. In-hospital mortality was 
significantly higher (30.7% vs 10.8%) in patients 
with augmented daptomycin clearance [29]. Also, 
Vancomycin standard dosages did not achieve the 
PK/PD target (AUC24/MIC) in about 33% of pa-
tients treated for MRSA bacteremia, in the absence 
of RRT, cardiac surgery and malignancy [30]. In pa-
tients with infective endocarditis, including left- and 
right-sided, a retrospective study focusing on day 
1PK/PD of vancomycin AUC0-24/MIC showed that 
target of ≤ 600 mg.hr/L (P =.047) was associated 
with treatment failure, and not as reported earlier 
of 400 mg.hr/L [31]. 
A prospective, multinational pharmacokinetic 
point-prevalence study including 8 β-lactam anti-
biotics. Two blood samples were taken from each 
patient during a single dosing interval. The primary 
PK/PD targets were free antibiotic concentrations 
above the MIC of the pathogen at both 50% (50% 
ƒT>MIC) and 100% (100% ƒT>MIC) of the dosing 
interval. The study found positive clinical outcome 
associated with increasing 50% ƒT>MIC and 100% 
ƒT>MIC ratios (OR, 1.02 and 1.56, respectively; P 
<.03), with significant interaction with sickness se-
verity status. The results suggested that ICU clini-
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cians mustcustomize dosing strategies for the cri-
tically sick patients due to β-lactams significant PK 
variability, to assure drug target exposure and to 
optimize the outcome of the treated patients [32]. 
Moreover, another advantage of adequate tar-
get attainment in septic patient is the prevention 
of mutant selection due to antimicrobials under 
exposure, knowingly that bacterial population cau-
sing sepsis are mostly heterogenous in their an-
timicrobial susceptibility with higher MIC-mutants 
[33, 34], mutant bacteria with elevated MIC need 
higher antimicrobial doses to overcome the mutant 
selection “window” (MSW), and to bridge the gap 
to the “novel” target as a PK/PDefficacy index (Fi-
gure 4) [34, 35]. 
Intermittent versus continuous infusion 
β-lactam
The administration of antimicrobials is customarily 
given as intermittent bolus (IB) in most of the hos-
pitals worldwide, and probably all ICUs of our re-
gion because the continuous infusion (CI) method 
is considered not practical, and not accepted as the 
standard of care in our region (personal knowled-
ge). However, several studies were conducted com-
paring clinical efficacy of CI versus IB as a surrogate 
for the probability of target attainment (PTA) as 
PK/PD efficacy index. A Monte Carol Simulation-
based study for standard doses of the β-lactams 
(ceftobiprole, meropenem, piperacillin/tazobactam 
and cefepime) whether they reach>50% ƒT > MIC 
and to achieve >0.9 PTA, only CI and/or high doses 
IB were required [36]. In a multicenter survey stu-
dy performed to describe the various approaches 
used for β-lactam TDM in ICUs, different PK/PD 
target attainments were reached through different 
dosing methods; continuous infusion (CI) versus in-
termittent bolus (IB) when ƒT > 4xMIC was 100% 
for CI and ranged 40 – 70% for IB [37]. Another 
multicenter PK/PD study comparing CI versus IB 
of β-lactam demonstrated that antimicrobial level 
above MIC (T>MIC) was significantly achieved for 
CI (82% versus 29%, P = .001) with higher clinical 
cure rate (70% versus 43% P = .037), but the-
re was no difference in the secondary endpoint 
of ICU free days or survival by hospital discharge 
Figure 4:  The PK/PD patterns of bacterial killing, note the elevated MIC for mutant bacteria (Mutant 
prevention concentration (MPC), which made less antimicrobial exposure for the three PK/
PD indices. (A) ƒT>MPC shows the time spent above the antimicrobial MPC for the treated 
bacteria, (B) ƒ Cmax/MPC which is the maximum concentration an antimicrobial reach over 
MPC, and (C) ƒAUC/MPC. The preferable many folds above MIC for T>MPC is difficult to 
attain with regular antimicrobial doses, and the same for the other two PK/PD indices. MSW: 
mutant selection window [34, 35].
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[38]. In a succeeding clinical trial in critically septic 
patients evaluating the endpoint of the number 
of alive ICU-free days at Day 28, and secondary 
endpoints of 90-day survival, clinical cure 14 days 
post antibiotic cessation, alive organ failure–free 
days at Day 14, and duration of bacteremia, there 
was no difference in the measured endpoints bet-
ween CI or IBβ-lactam infusion [39]. A two-center 
study and 140 patients equally assigned in critically 
ill patients with severe sepsis not receiving RRT, CI 
versus IB demonstrated higher clinical cure rates 
(56 versus 34 %, p = 0.011) and had better PK/
PD target attainment (97 versus 70 %, p < 0.001). 
Continuous β-lactam infusion may be mostly ad-
vantageous for critically ill patients with high seve-
rity scores and not receiving RRT [40]. 
A meta-analysis by J.A. Roberts and his group 
identified three clinical trials on β-Lactam in Severe 
Sepsis, CI versus IB, with 632 patients, there was no 
difference in clinical cure rates after adjustment for 
other covariates by multivariate analysis, however 
borderline significance of decreased mortality in the 
CI group (P = 0.045) was observed [41]. Linezolid 
was administered as IB versus CI, the CI gave an ear-
lier and stable steady state level above the treated 
bacterial MIC with significantly achieving the target 
AUC/MIC (P <0.05) at 80 – 120, though both 
groups did not differ significantly in the clinical res-
ponse, probably due to small number of patients 
recruited for the study [42]. 
So far, there is not sufficient convincing evidence 
to recommend wide scale use of CI; no differen-
ces in mortality, infection recurrence, clinical cure, 
super-infection post-therapy, and safety outcomes 
were similar. CI strategy may be employed in some 
clinical scenarios like in critically sick patients with 
severe infections, with normal renal function and 
lung infections, and with resistant pathogens. Still 
questions on CI of β-lactams need to be answered, 
like the effect of CI when there are additional con-
founders, RRT and renal failure, and various organs 
infections. Additional large sample size prospective 
randomized trials are needed, utilizing PK/PD princi-
ples and focusing on special categories of patients, 
being on ventilator or not, having only sepsis, sepsis 
with shock, MODS, gram-positive versus gram-ne-
gative bacteria, and the level of bacterial MICs [43]. 
PK/PD principles of antimicrobials dosing 
when dealing withBiofilm
A biofilm is a structured consortium of bacteria 
embedded in a self-produced polymer matrix con-
sisting of polysaccharide, protein and extracellular 
DNA. Bacterial biofilms are resistant to antibio-
tics, disinfectant chemicals and to phagocytosis 
and other components of the innate and adaptive 
inflammatory defense system of the body.” [44]. 
Biofilm is usually produced by sessile bacteria, and 
it can be produced on the surfaces of the host 
tissues and the embedded prosthetic materials in 
human tissues [45, 46]. However, the same pat-
terns of bacterial killing hold true for sessile as 
in planktonic bacteria, whether time dependency 
(T>MIC),concentration dependency (Cmax/MIC) 
ormixed patterns (AUC/MIC), nonetheless, hig-
her antimicrobial levels are needed, where mature 
biofilm require remarkably higher levels of antimi-
crobials than a young biofilm. PK/PD indices here 
are being dealt as related to T > Minimum biofilm 
inhibition concentration (T>MBIC) and T > mini-
mum biofilm eradication concentration (T>MBEC), 
Cmax/MBIC and Cmax/MBEC), and AUC/MBIC 
and AUC/MBEC are probably the targets for dosing 
with respected antimicrobials according to type of 
killing, but so far in vivo studies are lacking, proba-
bly antimicrobials with wide TI are candidates [47]. 
In addition to the known bacterial killing index of 
imipenem (T>MBIC) for biofilm bacteria, an inter-
esting phenomenon for imipenem as a β-lactam is 
that “the AUC/MIC of imipenem showed a better 
correlation with the efficacy for biofilm infections 
(R2 = 0.89) than planktonic cell infections (R2 = 
0.38)” when was used to treat Pseudomonas aeru-
ginosa strain in a mouse lung model, it behaved 
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like colistin that follow AUC/MIC, this phenomena 
needs further clarification in future in vitro and in 
vivo studies, [48]. Another notion in some reports 
is that using combination antimicrobials to treat 
infections with established biofilm may be more 
effective than the use of a mono-active antimi-
crobial agent, in an in vitro study based on bio-
films recovered from patients with infected joints, 
azithromycin in combination with daptomycin was 
found more effective than either one alone [49], 
other antibiotics behaved the same when used as 
monotherapy, showing advantage for combination 
when using biofilm active agent, and rifampin was 
the most active agent against biofilms when used 
in combination [50]. Agents that directly work on 
biofilms are under development, in the future, an-
tibiofilm agents may be used alongside as stan-
dard anti-infective agents in combating all types 
of prosthetic devices [51]. 
In conclusion, the evolving field of PK/PD in the 
treatment of critically septic patients is still looking 
for clear answers from in vivo studies; to define tar-
gets for different infections, microorganisms and 
antimicrobial agents, to delineate better, which 
groups of patients benefit more of continuous 
infusion compared with intermittent bolus dose 
strategy. To recommend what differently it can 
be done for the prosthetic devices infections with 
established biofilms, and to demonstrate a clear 
PK/PD-dependent clinical data focusing on better 
recovery, survival, cost containment and long-term 
prognosis. 
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